Corporate Spotlight
Firebrick Pharma (ASX:FRE) is an Australian pharmaceutical developer focused on developing and commercializing novel formulations and uses of povidone-iodine. After more than 10 years of R&D including multiple human clinical trials, Firebrick's first product, Nasodine® Nasal Spray, is now available
View the full Corporate Spotlight
INTERVIEW WITH EXEC CHAIRMAN - PETER MOLLOY
Latest Threads
See All Discussions
Corporate Spotlight
Timeline
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
View More |